Evaluating adherence to medication in children and adolescents with HIV

Archives of Disease in Childhood

Volumn 94, Issue 12, 2009, Pages 970-973

  Khan, M ^a,c   Song, X ^a,b,c   Williams, K ^c   Bright, K ^c   Sill, A ^c   Rakhmanina, N ^a,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; COHORT ANALYSIS; DATA BASE; FEMALE; FISHER EXACT TEST; HOME DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PHARMACY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SELF REPORT; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADOLESCENT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICATION ADHERENCE; PHARMACIES; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 73249115949     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.156232     Document Type: Article

References (22)

1. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008;46:1751-60.
2. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103.
3. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006;118:e1745-57.
4. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
6. Chesney MA, et al. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006;43(Suppl 1):s149-55.
7. Townsend ML, Jackson GL, Smith R, Wilson KH, et al. Association between pharmacy medication refill-based adherence rates and CD4 count and viral-load responses: a retrospective analysis in treatment- experienced adults with HIV. Clin Ther 2007;29:711-16.
8. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf 2005;14:789- 93.
9. van Rossum AM, Bergshoeff AS, Fraaij PL, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21:743-7.
10. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003;157:249-55.
11. Saito A, Foca M, Viani RM, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 2008;121:e513-21.
12. Martin S, Elliott-DeSorbo DK, Wolters PL, et al. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J 2007;26:61-7.
13. Glikman D, Walsh L, Valkenburg J, et al. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications. Pediatrics 2007;119: e1142-8.
14. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS 1999;13:535-44.
15. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 2002;288:1594-602.
16. Colombo J. Establishing pharmaceutical care services in an HIV clinic. J Am Pharm Assoc (Washington) 1997;NS37:581-92; quiz 593-4.
17. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002;109:e61.
18. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000;1:36-46.
19. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007;119:e1371-83.
20. Murphy DA, Wilson CM, Durakó SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001;13:27-40.
21. Marhefka SL, Tepper VJ, Farley JJ, et al. Brief report: assessing adherence to pediatric antiretroviral regimens using the 24-hour recall interview. J Pediatr Psychol 2006;31:989-94.
22. Rao D, Kekwaletswe TC, Hosek S, et al. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care 2007;19:28-33.